Enterprise Therapeutics’ Post

📣 Join us for our upcoming webinar: Unlocking the full potential of immunopeptidomics with the timsTOF Ultra 📅 October 29, 2024 11:00 am - 12:00 pm EDT, 4:00 - 5:00 pm CET Why to join this webinar: The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process The time is ripe to bring immunopeptidomics into clinical routine https://lnkd.in/efUZwFye

Today I came across with a very recent review by Maryam Rahnama, Mohammad Heidari, Zahra Poursalehi, and Ali Golchin, focusing on global trends in EV-based clinical applications. It was not surprising to see the focus is mostly on cancer and wound healing, yet the confirmation was helpful in the sense that trend is still supported in the similar direction by the growing understanding of the field. What was more surprising to me, on the other hand, was to see that MSCs are by far the mostly used cell source in the investigated studies. Even though I was aware that MSCs gained much higher attraction recently, I was not expecting such a domination. Moreover, it felt satisfactory to see that tangential flow filtration (TFF) started to demonstrate itself in the statistics as well. The comparison between TFF and ultracentrifugation stating that the former has advantages like higher yield and purity as well as better suitability for downstream applications was more or less what I would like to point out when I speak about our TFF offers by HansaBioMed Life Sciences Ltd. If you are interested in further reading: https://lnkd.in/dd6HYHkz #extracellularvesicles #exosomes #evdiagnostics #evtherapeutics

🧪 #FIPO: launch of the 3rd cohort in the clinical trial The scientific council has given the green light for the third dose in the ascending phase of our FIPO clinical trial. This Phase I/II trial tests the safety and efficacy of XON7 in patients with solid tumors. Key updates: ✅ Safety validated: after cohorts at 1.5 mg/kg and 3 mg/kg, the safety of XON7 has been confirmed. 👩⚕️ New cohort: 3 patients with solid tumors are now being treated at 6 mg/kg across our Foch, Lyon, and Toulouse centers. 📈 Ascending phase: we are progressively increasing doses to ensure safety and assess the benefit/risk ratio of XON7. 💫 Hope for patients: XON7 represents a new hope for patients who have not responded to current treatments. 🔍 More information in our carousel. #ClinicalTrial #XON7 #Biotech #Innovation #PatientCare

How dexamethasone protects against severe COVID-19 Dexamethasone was used as an effective drug for severe COVID cases during the pandemic. A study integrating single-cell and bulk transcriptomics in clinical cohorts reveals the molecular basis of its immunomodulatory effect and also provides a framework for the future development of companion diagnostics for patient stratification in precision medicine. The authors show that dexamethasone-induced transcriptional changes were confined to a specific monocyte state and molecular treatment responses in monocytes were directly linked to clinical outcome. They also found that reversal of dysregulated monocyte signatures in dexamethasone-treated COVID-19 survivors and monocyte single-cell signatures stratified blood samples could be used for treatment response. #sciencenewshighlights #ScienceMission https://lnkd.in/gbhz_5rp https://lnkd.in/gpMi5dY6

Bioxodes - Did you know? #DYK? Bioxodes is developing a medicine to decrease mortality rates and facilitate a quicker and improved recovery for patients following a hemorrhagic stroke (bleeding in the brain), an often-deadly disease for which no medicines exist at the moment. The drug – called BIOX-101 - is still being tested: first in laboratories, now in patients in clinical tests. But we already know from preclinical studies that: 🔻 It prevents blood clotting but does not increase the risk of bleeding, 🔻 It prevents the damaging neuroinflammation at the site of the stroke, and 🔻 It reduces neuron mortality. These are promising findings, and Bioxodes hopes to show more positive results from trials with patients, which are now taking place in Belgium

Today, September 7, we acknowledge World Duchenne Muscular Dystrophy Awareness Day and extend our deepest gratitude to the Duchenne community and C-Path’s Duchenne Regulatory Science Consortium members for their tireless dedication to advancing treatments for DMD. To combat the many challenges posed by this disease, D-RSC has created an integrated database of patient-level clinical data from DMD studies, and several drug development tools available to the Duchenne community with permissions. Established by C-Path and Parent Project Muscular Dystrophy, D-RSC, in partnership with CDISC, has also developed standard terminology and authored the Duchenne Muscular Dystrophy Therapeutic Area User Guide and the Cardiac Imaging Supplement currently out for public review until September 30.   We are proud to continue this work and are grateful for the community’s ongoing collaboration. For more information, visit c-path.org/programs/d-rsc. To view the Cardiac Imaging Supplement, visit: https://lnkd.in/g8ujGTsV   Ramona Belfiore-Oshan, Pat Furlong   #CPath #DMDawareness #WDAD2024 #musculardystrophy #raredisease #drugdevelopment #datasharing #globalhealth #collaboration #CDISC

Did you know? #DYK? Bioxodes is developing a medicine to decrease mortality rates and facilitate a quicker and improved recovery for patients following a hemorrhagic stroke (bleeding in the brain), an often-deadly disease for which no medicines exist at the moment. The drug – called BIOX-101 - is still being tested: first in laboratories, now in patients in clinical tests. But we already know from preclinical studies that: 🔻 It prevents blood clotting but does not increase the risk of bleeding, 🔻 It prevents the damaging neuroinflammation at the site of the stroke, and 🔻 It reduces neuron mortality. These are promising findings, and Bioxodes hopes to show more positive results from trials with patients, which are now taking place in Belgium. #strokeawareness #voiceofstroke #hemorrhagicstroke #patientcare

NONCLINICAL PROGRAM POC Rodent Studies of PK, Efficacy, and Tolerability of Continuous LLD. From 2 minutes - iPRECIO Programmable Pump use. Now in Clinical Trials https://lnkd.in/gwy7MXhq #drugdelivery #continousinfusion #multiplemyeloma #lenalidomide https://lnkd.in/gf2VrYG6

Explore axoCells™ atrial and ventricular cardiomyocytes for robust, chamber-specific in vitro models. Here you can see our Senior Scientific Support Manager Steven Broadbent describe the results from a compound treatment assay we conducted in collaboration with innoVitro. We demonstrated that distinct pharmacological effects can be observed between axoCells atrial and ventricular cardiomyocytes when using the FLEXcyte 96 platform to assess contractility. Click here to access the full webinar recording of "Building chamber-specific cardiac models with iPSCs": https://hubs.la/Q02CtCsX0 If you'd like to read the full data set, click here for our application note: https://hubs.la/Q02CtBZ30 If you're working with iPSC-derived cardiomyocytes and would like to discuss how Axol Bioscience could help you to unlock the benefits of iPSC technology, get in touch at operations@axolbio.com #iPSCs #cardiotoxicity #CiPA #DrugDiscovery #AtrialFibrillation

Early trials presented at #ESMO24 report promising data with claudin-targeted antibody–drug conjugates (#ADCs) in patients with #AdvancedSolidTumours. Valentina Gambardella explains that this novel therapeutic approach, which combines the specificity of targeted agents with the potency of ADCs, represents a significant advance in the pursuit of #PrecisionOncology. The results of phase I studies are encouraging, with good responses and manageable safety observed in heavily pretreated patients with poor prognosis. 📌Read more about the study data on the #ESMODailyReporter https://ow.ly/fOnm50TnIIV